How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

677 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

301. Effects of the Atkins Diet Versus a Low Fat Diet on Inflammation

but not limited to phentermine, sibutramine, orlistat, or over the counter weight loss products History of an eating disorder or significant disordered eating behaviors such as binging/purging, abuse of laxatives or diuretics History of established renal or hepatic disease History of prior bariatric surgery Subjects who report routine tobacco use Subjects on Angiotensin receptor blockers (medications such as but not limited too Adicant, Losartan, Avapro, Diovan, Micardis, Teveten, Candesarten/thiazide

2009 Clinical Trials

302. SUCCESS Tracking Study

., SSRIs, steroids, Ritalin) Taking prescription weight-loss drugs (Phentermine, Sibutramine, Orlistat, etc…) Have undergone, or plan to undergo, weight loss surgery (e.g. gastric bypass, lap band, duodenal switch) in the next 6 1/3 years Plan to undergo weight-altering cosmetic surgery procedures (e.g. breast reduction/augmentation, tummy tuck, liposuction, or other skin removal procedures) in the next 6 1/3 years Contacts and Locations Go to Information from the National Library of Medicine To learn

2009 Clinical Trials

303. Hemodynamics, Salt Sensitivity and Body Composition in Patients With Morbid Obesity

Medical treatment with sibutramine. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT00998465 Locations Layout table for location information Denmark University Hospital Koege, Department of Clinical Physiology and Nuclear Medicine Koege, Denmark, DK

2009 Clinical Trials

304. A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes

label. Have taken more than 1 week within 1 month prior to the study start any glucose-lowering medications not included above either alone or in combination formulations, or have used a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phenylpropanolamine, rimonabant or similar over-the-counter medications). Have taken any insulin other than Glargine within the 3 months prior to study start for more than 1 week. Are receiving chronic (lasting longer than 2 weeks

2009 Clinical Trials

305. A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus

of the patient or for the purposes of the study Exclusion Criteria: Use of an excluded medication/therapy including any of the following: Steroids Oral hypoglycemic agents Chemotherapy and radiation Immunosupressants Nicotinamide >100 mg per day Any drugs containing sibutramine Female patients with a positive pregnancy test or who are lactating Adult patients with body weight <45 kg; adolescent patients with body weight <30 kg; 10- and 11-year-old patients with body weight <25 kg History of cancer or have

2009 Clinical Trials

306. The Effects of Exenatide After Gastric Restriction

), Have experienced hypersensitivity reaction or a worsening of glycemic control on Byetta® (exenatide), Patients with end stage renal disease or severe renal impairment, Patients with severe gastrointestinal disease, including gastroparesis, Liver function tests 2.5 standard deviations above normal values, Contraindication for bariatric surgery, Treatment with exenatide (Byetta) in the last three months, Currently using or have used within three months before this trial: sibutramine, orlistat

2009 Clinical Trials

307. Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia

serious disease or condition at Visit 1 that may reduce life expectancy, impair successful management according to the protocol, or make the participant unsuitable to receive study medication. Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including: Orlistat Sibutramine Isotretinoin Tacrolimus Probucol Systemic corticosteroids

2009 Clinical Trials

308. A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

or hypersensitivity to exenatide, sitagliptin or excipients contained in exenatide or sitagliptin. Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 1 month of screening. Are currently treated with any of the following excluded medications: Thiazolidinediones (TZD) within 3 months of screening. Sulfonylurea (SU) within 3 months of screening. Dipeptidyl peptidase-4 [DPP-4] inhibitors, with the exception of sitagliptin, within 3

2009 Clinical Trials

309. Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Cholestin red yeast rice fish oils plant sterols and stanols orlistat sibutramine isotretinoin tacrolimus Probucol Systemic corticosteroids and androgens Potent CYP3A4 inhibitors Cyclosporine Erythromycin Clarithromycin Telithromycin human immunodeficiency virus protease inhibitors amiodarone diltiazem verapamil nefazodone grapefruit juice Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2009 Clinical Trials

310. Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care

and then follows a decision tree for additional interventions based on early treatment response is superior to standard behavioral treatment. Condition or disease Intervention/treatment Phase Obesity Binge Eating Behavioral: Behavioral Weight Loss Behavioral: Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy Drug: Placebo Drug: Sibutramine/Orlistat Not Applicable Detailed Description: The stepped-care arm of this study included an obesity medication intervention. At the start of the study (...) , the active medication was sibutramine and was compared to a placebo control. On 10/8/2010, Abbott Laboratories withdrew their obesity drug sibutramine (Meridia) from the market in light of clinical trial data pointing to an increased risk for stroke and myocardial infarction. In response to this event, the investigators submitted an IRB amendment to change the active obesity medication from sibutramine to Orlistat. The IRB amendment was approved on 11/4/2010. The PI received approval from NIH/NIDDK

2009 Clinical Trials

311. To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake

hypertension Positive result of HIV, hepatitis B or hepatitis C screens Recent treatment (i.e., within 1 month of the screening visit) with over-the-counter weight loss products or appetite suppressants (including herbal weight loss agents), or within 3 months with a prescription anti-obesity drug (e.g., phentermine, sibutramine, orlistat) Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to screening Contacts and Locations Go to Information from

2009 Clinical Trials

312. Binge Eating and Chromium Study

to significantly influence appetite or weight [i.e., over-the-counter appetite suppressants that contain phentermine or sibutramine, atypical antipsychotic agents with high weight gain liability (such as olanzapine, risperidone, etc), prednisone, etc.]; Fasting glucose level > 126 mg/dL (indicative of diabetes); and Creatinine level indicating renal insufficiency (> 1.0 for women; > 1.2 for men). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2009 Clinical Trials

313. Effect of Antipsychotics on Appetite Regulation

of medications to treat metabolic and endocrine abnormalities, corticosteroids, over-the-counter appetite suppressants that contain phentermine or Sibutramine; Active involvement with a weight loss program (i.e., Weight Watchers); Serious or unstable medical illness which requires ongoing treatment with medication (this does not include hypertension); Anemia; At serious suicidal risk; Current substance abuse or dependence; For female subjects, pregnancy or nursing (because pregnancy may influence appetite

2009 Clinical Trials

314. Study of Treatment for Adolescents With Bulimia Nervosa

on drugs or alcohol; current diagnosis of anorexia nervosa or weight less that 85% IBW; physical conditions (e.g. diabetes mellitus, pregnancy) known to influence eating or weight; currently taking medication for co-morbid conditions for less than 2-months; currently taking medications that may induce weight loss, e.g., appetite suppressants such as sibutramine, phentermine, and xenical, unless the participant is willing to withdraw from such medications; currently taking medications for symptoms of BN

2009 Clinical Trials

315. A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Thyroid replacement therapy Antidepressant agents Drugs known to affect body weight, including prescription medications (e.g. orlistat [XENICAL®], sibutramine [MERIDIA®], topiramate [TOPAMAX®]) and over the counter antiobesity agents Exclusion Criteria: Has ever been exposed to exenatide (exenatide once weekly [exenatide LAR], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) analog Has received any investigational drug within one month (or five half-lives

2009 Clinical Trials

316. Evaluation of the Remote Intervention for Diet and Exercise (RIDE)

medications such as sibutramine, antipsychotic medications such as olanzapine, ephedrine, and diuretics). Diagnosed with uncontrolled hypertension (high blood pressure), defined as systolic blood pressure >159 mmHg & diastolic blood pressure >99 mmHg. For females, current pregnancy, or plans to become pregnant in the duration of the study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2009 Clinical Trials

317. The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

to treat obesity including medications obtained over the counter or internet, orlistat (Xenical, Alli), sibutramine (Meridia), topiramate (with or without phentermine (Qsymia), phentermine (Adipex P) or lorcaserin (Belviq) within the past 6 months History of an eating disorder including anorexia or bulimia History of surgery for the treatment of obesity (gastric banding, gastric bypass) Diagnosis of type 1 or type 2 diabetes mellitus according to American Diabetes Association guidelines Previous

2009 Clinical Trials

318. USDA Behavior, Motivation & Nutrition Study

in the last 6 months Multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease Menopause confirmed Unable to refrain from smoking for five hours (self-report) Unable to refrain from consuming alcohol for two days (self-report) Weight change > 10 lbs in the preceding 6 months Chronic corticosteroid use Oral corticosteroids used more than twice in the last 12 months Hormonal contraceptives Antipsychotic, anti-anxiety and anti-depressant medications Beta adrenergic blockers Sibutramine, orlistat

2009 Clinical Trials

319. Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

medications (e.g. sibutramine, orlistat, rimonabant), History of pancreatitis. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT00851903 Locations Layout table for location information United States, New Jersey Sanofi-Aventis Administrative Office

2009 Clinical Trials

320. Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes

or herbal remedies for weight loss (e.g., sibutramine, orlistat, amphetamines, phentermine, and ma huang) or use of these substances within the past 3 months Current or recent history (past 12 months) of drug, alcohol or chemical abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor) Pregnant, breast-feeding or female of child-bearing potential who is unwilling to commit to the use of a medically approved form of contraception throughout

2009 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>